<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01714557</url>
  </required_header>
  <id_info>
    <org_study_id>TZP-HEM-20120608</org_study_id>
    <nct_id>NCT01714557</nct_id>
  </id_info>
  <brief_title>Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Piperacillin/Tazobactam for Prophylaxis in Patients of Neutropenia After Hematopoietic Stem Cell Transplantation - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neutropenia is very common in patients received hematopoietic stem cell transplantation, with
      median duration of about 14 days. Almost all neutropenia will suffer from febrile without
      prophylactic antibiotics. IDSA recommended fluoroquinolones as prophylaxis in neutropenia
      patients of high risks, while in China, major pathogens possess high resistance to
      fluoroquinolones. It is not clear whether prophylaxis is of benefit, nor the appropriate
      prophylaxis regimen.

      The current study will evaluate the three different regimen:

        1. No prophylaxic antibiotic

        2. Piperacillin as prophylaxis for neutropenia patients. Piperacillin has anti-pseudomonas
           activity.

        3. Piperacillin/tazobactam as prophylaxis for neutropenia patients. Piperacillin/tazobactam
           has highest susceptibility rate among common anti-pseudomonas antibiotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Swab culture (skin, pharyngeal, nasal, anus) when administered into laminar flow room
           after transplantation.

        2. Randomize the neutropenia patients into 3 groups.

        3. Receive 3 regimen.

        4. Full record of clinical data, including background diseases, previous antibiotics within
           90 days, febrile or not at the TOC.

        5. For patients developed febrile, imipenem will be prescribed, even if the patient
           received no prophylaxis. At the same time, the follow-up ended.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>febrile rate</measure>
    <time_frame>3 weeks after beginning of prophylaxis</time_frame>
    <description>In both group, how many patients developed febrile.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiologic efficacy in febrile patients</measure>
    <time_frame>3 weeks after beginning of prophylaxis</time_frame>
    <description>The success rate and failure rate will be calculated.
The microbiologic culture is positive at 3 weeks of prophylaxis, showing pathogen sensitive to Piperacillin/tazobactam, the case will be evaluated as breakthrough infection, that means microbiologic failure.
The microbiologic culture is negative at 3 weeks of prophylaxis,, or positive fungus or non-typical organisms, the case will be evaluated as microbiologic success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery rate from neutropenia</measure>
    <time_frame>3 weeks after beginning of prophylaxis</time_frame>
    <description>How many patients reached the ANC &gt; 0.5Ã—109/L more than 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>3 weeks after beginning of prophylaxis</time_frame>
    <description>How many patients developed unexpected medical events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of drug and hospital-stay</measure>
    <time_frame>3 weeks after beginning of prophylaxis</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Neutropenia</condition>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>No prophylaxis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>piperacillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>piperacillin/tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin</intervention_name>
    <description>4.0g q8h 3-5 days</description>
    <arm_group_label>piperacillin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin-tazobactam combination product</intervention_name>
    <description>4.5g q8h 3-5 days</description>
    <arm_group_label>piperacillin/tazobactam</arm_group_label>
    <other_name>Tazocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 13-65 years

          -  Received Autologous or Allogeneic hematopoietic stem cell transplantation.

          -  ECOG score 0-1.

          -  ICF is available.

        Exclusion Criteria:

          -  Allergic to any therapy drug.

          -  Documented infection before neutropenia.

          -  Renal dysfunction.

          -  Suffering from central nervous system or mental disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>wenrong huang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Employee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA general hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wenrong Huang, Doctor</last_name>
      <email>huangwr301@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2012</study_first_posted>
  <last_update_submitted>October 25, 2012</last_update_submitted>
  <last_update_submitted_qc>October 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Wenrong Huang</investigator_full_name>
    <investigator_title>Associate director, Hematology, Chinese PLA General hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

